Trial Profile
A Non-interventional, Multicenter Study of the Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Feb 2020
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Trabectedin (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms Renaissance
- 28 Feb 2018 New trial record